Company News

Gmax Biopharm Appointed Two Vice Presidents


Gmax Biopharm LLC. Recently appointed Dr. Yi(Gloria)Wang and Mr. Alex Hie Lin Wong Vice Presidents to strengthen Gmax Biopharm in clinical development, aiming to deliver the innovative therapeutics to the global patients in rapid and stable fashion.

Before Gmax Biopharm, Dr. Wang was Chief Medical Officer in a biopharmaceutical and a cellular therapy company. She has 15 years’experience in the clinical development for innovative therapeutics including small molecule, monoclonal antibody, recombinant protein, and therapeutic cell (CAR-T and stem cell), with insights and hands-on experience in post-marketing life-cycle management in the industry. Dr. Wang started her clinical development career when she worked in Johns Hopkins University where she led a cross functional team in conducting global trials. She used to work in Novartis, United Therapeutics, and local Pharmaceutical companies and set an excellent track record in the industry, successfully launched products in the global market. Dr. Wang received her M.D. from Tongji University and Ph.D. in Oncology from Fudan University. She was trained in a  postdoctoral program in the University of Massachusetts Medical School (UMASS medical school) and Johns Hopkins Hospital for 2 years and 4 years respectively. Dr Wang will be responsible for the clinical development in Cardiovascular Therapeutic Area. She will lead the development projects for GMA301 that has been granted orphan drug designation by FDA for the indication development in Pulmonary Arterial Hypertension.

Mr.Wong received his Master of Medical Science, MBA in Life Science and MPA in United Kingdom. He was holding the roles of regional medical director and assistant clinical director when he was at Takeda Pharmaceutical, Sanofi and local companies. With more than 15 years’experience in clinical development, extensively involved in global clinical trials from Phase I to III in Cardiovascular and Metabolic Therapeutic Areas, Mr Wong will be responsible for the clinical development in Metabolic Therapeutic Area.